News Lookbook Collaborate Salaries Per Diem Marketplace Tools Referrals

B-Seen

The eye care industry's career marketplace — free for job seekers and independent practices.

Professionals

Find a Job
Create Profile
Lookbook
Collaborate

Pay & Career

Salary Transparency
Methodology
Career Tools
Field of View News

Employers

Post a Job
Corporate Partners
Pricing
Equipment Marketplace

Connect

About Us
Contact

Privacy Terms Cookies Accessibility Privacy Requests

B-Seen is operated by B-SEEN, LLC, 300 Needham St, Suite 4, Newton, MA, USA.

B-Seen

The eye care industry's career marketplace — free for job seekers and independent practices because the cost of hiring shouldn't be a barrier for the small, doctor-owned offices that are the backbone of eye care.

Professionals

Find a Job
Create Profile
Lookbook
Collaborate

Pay & Career

Salary Transparency
Methodology
Career Tools
Field of View News

Employers

Post a Job
Corporate Partners
Pricing
Equipment Marketplace

Connect

About Us
Contact

Privacy Terms Cookies Accessibility Privacy Requests

B-Seen is operated by B-SEEN, LLC, 300 Needham St, Suite 4, Newton, MA, USA. Contact: legal@b-seen.io

FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component | Field of View | B-Seen

Article

Back to Feed

FDA Approvals

FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component

FDA3d ago1 min read

On September 24, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with lenvatinib (Lenvima, Eisai Inc.) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC).

Read full article on FDA

Discussion

No comments yet. Be the first to share your thoughts.